The subthalamic nucleus and the placebo effect in Parkinson's disease

Alexander, 1986, Parallel organization of functionally segregated circuits linking basal ganglia and cortex, Annu Rev Neurosci, 9, 357, 10.1146/annurev.ne.09.030186.002041 Benedetti, 2013, Placebo and the new physiology of the doctor-patient relationship, Physiol Rev, 93, 1207, 10.1152/physrev.00043.2012 Benedetti, 2014, Placebo effects: from the neurobiological paradigm to translational implications, Neuron, 84, 623, 10.1016/j.neuron.2014.10.023 Benedetti, 2014 Benedetti, 2014, Creating placebo responders and nonresponders in the laboratory: boons and banes, Pain Manag, 4, 165, 10.2217/pmt.14.11 Benedetti, 2003, Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses, J Neurosci, 23, 4315, 10.1523/JNEUROSCI.23-10-04315.2003 Benedetti, 2004, Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus, Nat Neurosci, 7, 587, 10.1038/nn1250 Benedetti, 2009, Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response, J Physiol, 587, 3869, 10.1113/jphysiol.2009.169425 Benedetti, 2016, Teaching neurons to respond to placebos, J Physiol, 594, 5647, 10.1113/JP271322 Bergman, 1994, The primate subthalamic nucleus. II Neuronal activity in the MPTP model of parkinsonism, J Neurophysiol, 72, 507, 10.1152/jn.1994.72.2.507 Blandini, 2000, Functional changes of the basal ganglia circuitry in Parkinson's disease, Prog Neurobiol, 62, 63, 10.1016/S0301-0082(99)00067-2 Bolam, 2000, Synaptic organisation of the basal ganglia, J Anat, 196, 527, 10.1046/j.1469-7580.2000.19640527.x Carlino, 2014, Pain and the context, Nat Rev Rheumatol, 10, 348, 10.1038/nrrheum.2014.17 Carlino, 2019, Verbal communication about drug dosage balances drug reduction in Parkinson's disease: behavioral and electrophysiological evidences, Parkinsonism Relat Disord, 65, 184, 10.1016/j.parkreldis.2019.06.015 Colagiuri, 2015, The placebo effect: from concepts to genes, Neuroscience, 307, 171, 10.1016/j.neuroscience.2015.08.017 De la Fuente-Fernández, 2001, Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease, Science, 293, 1164, 10.1126/science.1060937 De la Fuente-Fernández, 2002, Dopamine release in human ventral striatum and expectation of reward, Behav Brain Res, 136, 359, 10.1016/S0166-4328(02)00130-4 Deecke, 1996, Planning, preparation, execution, and imagery of volitional action, Cogn Brain Res, 3, 59, 10.1016/0926-6410(95)00046-1 Diamond, 1985, Double-blind trial of pergolide for Parkinson's disease, Neurology, 35, 291, 10.1212/WNL.35.3.291 Enck, 2008, New insights into the placebo and nocebo responses, Neuron, 59, 195, 10.1016/j.neuron.2008.06.030 Finniss, 2010, Biological, clinical, and ethical advances of placebo effects, Lancet, 375, 686, 10.1016/S0140-6736(09)61706-2 Freude, 1987, Changes in Bereitschaftspotential during fatiguing and non-fatiguing hand movements, Eur J Appl Physiol Occup Physiol, 56, 105, 10.1007/BF00696384 Frisaldi, 2014, Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients, Cortex, 60, 3, 10.1016/j.cortex.2013.12.003 Frisaldi, 2017, The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning, Mov Disord, 32, 1474, 10.1002/mds.27142 Frisaldi, 2018, Placebo responders and nonresponders: what's new?, Pain Manag, 8, 405, 10.2217/pmt-2018-0054 Goetz, 2000, Objective changes in motor function during placebo treatment in PD, Neurology, 54, 710, 10.1212/WNL.54.3.710 Goetz, 2002, Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease, Mov Disord, 17, 283, 10.1002/mds.10024 Goetz, 2008, Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions, Mov Disord, 23, 690, 10.1002/mds.21894 Gracely, 1985, Clinicians’ expectations influence placebo analgesia, Lancet, 1, 43, 10.1016/S0140-6736(85)90984-5 Haber, 2003, The primate basal ganglia: parallel and integrative networks, J Chem Neuroanat, 26, 317, 10.1016/j.jchemneu.2003.10.003 Ikemoto, 1999, The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking, Brain Res Rev, 31, 6, 10.1016/S0165-0173(99)00023-5 Keitel, 2013, Motor and cognitive placebo−/nocebo-responses in Parkinson's disease patients with deep brain stimulation, Behav Brain Res, 250, 199, 10.1016/j.bbr.2013.04.051 Knutson, 2005, Functional magnetic resonance imaging of reward prediction, Curr Opin Neurol, 18, 411, 10.1097/01.wco.0000173463.24758.f6 Levy, 2001, Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease, J Neurophysiol, 86, 249, 10.1152/jn.2001.86.1.249 Lidstone, 2010, Effects of expectation on placebo-induced dopamine release in Parkinson disease, Arch Gen Psychiatry, 67, 857, 10.1001/archgenpsychiatry.2010.88 Limousin, 1998, Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease, N Engl J Med, 339, 1105, 10.1056/NEJM199810153391603 Lou, 2013, Effect of expectancy and personality on cortical excitability in Parkinson's disease, Mov Disord, 28, 1257, 10.1002/mds.25471 Lozano, 2000, Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine, Ann Neurol, 47, S141 McRae, 2004, Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial, Arch Gen Psychiatry, 61, 412, 10.1001/archpsyc.61.4.412 Mercado, 2006, Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation, Mov Disord, 21, 1457, 10.1002/mds.20935 Obeso, 2008, Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease, Mov Disord, 23, S548, 10.1002/mds.22062 Pollo, 2002, Expectation modulates the response to subthalamic nucleus stimulation in parkinsonian patients, Neuroreport, 13, 1383, 10.1097/00001756-200208070-00006 Postuma, 2015, MDS clinical diagnostic criteria for Parkinson's disease, Mov Disord, 30, 1591, 10.1002/mds.26424 Price, 2008, A comprehensive review of the placebo effect: recent advances and current thought, Annu Rev Psychol, 59, 565, 10.1146/annurev.psych.59.113006.095941 Schultz, 2002, Getting formal with dopamine and reward, Neuron, 36, 241, 10.1016/S0896-6273(02)00967-4 Schultz, 2000, Reward processing in primate orbitofrontal cortex and basal ganglia, Cereb Cortex, 10, 272, 10.1093/cercor/10.3.272 Shaibani, 2017, Placebo response in pain, fatigue, and performance: possible implications for neuromuscular disorders, Muscle Nerve, 56, 358, 10.1002/mus.25635 Shetty, 1999, The placebo response in Parkinson's disease. Parkinson Study Group, Clin Neuropharmacol, 22, 207 Shibasaki, 2006, What is the Bereitschaftspotential?, Clin Neurophysiol, 117, 2341, 10.1016/j.clinph.2006.04.025 Stefani, 2002, Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the “indirect pathway”, Clin Neurophysiol, 113, 91, 10.1016/S1388-2457(01)00683-6 Strafella, 2006, Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation, Neuroimage, 31, 1666, 10.1016/j.neuroimage.2006.02.005 Tracey, 2010, Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans, Nat Med, 16, 1277, 10.1038/nm.2229 Wager, 2015, The neuroscience of placebo effects: connecting context, learning and health, Nat Rev Neurosci, 16, 403, 10.1038/nrn3976 Benedetti, 2006, The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect, J Neurosci, 26, 12014, 10.1523/JNEUROSCI.2947-06.2006 Benedetti, 2011, Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors, Nat Med, 17, 1228, 10.1038/nm.2435 Benedetti, 2011, Hidden administration of drugs, Clin Pharmacol Ther, 90, 651, 10.1038/clpt.2011.206 Benedetti, 2011, How placebos change the patient's brain, Neuropsychopharmacology, 36, 339, 10.1038/npp.2010.81 Brody, 2000 Colloca, 2005, Placebos and painkillers: is mind as real as matter?, Nat Rev Neurosci, 6, 545, 10.1038/nrn1705 Colloca, 2004, Overt versus covert treatment for pain, anxiety, and Parkinson's disease, Lancet Neurol, 3, 679, 10.1016/S1474-4422(04)00908-1 De la Fuente-Fernández, 2002, The placebo effect in neurological disorders, Lancet Neurol, 1, 85, 10.1016/S1474-4422(02)00038-8 Diederich, 2008, The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies, Neurology, 71, 677, 10.1212/01.wnl.0000324635.49971.3d Galpern, 2012, Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations, Lancet Neurol, 11, 643, 10.1016/S1474-4422(12)70064-9 Gill, 2003, Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease, Nat Med, 9, 589, 10.1038/nm850 Goetz, 2008, Placebo influences on dyskinesia in Parkinson's disease, Mov Disord, 23, 700, 10.1002/mds.21897 Gross, 2011, Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial, Lancet Neurol, 10, 509, 10.1016/S1474-4422(11)70097-7 Hutchison, 1998, Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease, Ann Neurol, 44, 622, 10.1002/ana.410440407 Lang, 2006, Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease, Ann Neurol, 59, 459, 10.1002/ana.20737 Limousin, 1997, Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease, Ann Neurol, 42, 283, 10.1002/ana.410420303 Marks, 2008, Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2eneurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial, Lancet Neurol, 7, 400, 10.1016/S1474-4422(08)70065-6 Marks, 2010, Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial, Lancet Neurol, 9, 1164, 10.1016/S1474-4422(10)70254-4 Olanow, 2003, A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease, Ann Neurol, 54, 403, 10.1002/ana.10720 Parent, 1995, Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry, Brain Res Rev, 20, 128, 10.1016/0165-0173(94)00008-D Péron, 2013, Subthalamic nucleus: a key structure for emotional component synchronization in humans, Neurosci Biobehav Rev, 37, 358, 10.1016/j.neubiorev.2013.01.001 Petrovic, 2005, Placebo in emotional processing e induced expectations of anxiety relief activate a generalized modulatory network, Neuron, 46, 957, 10.1016/j.neuron.2005.05.023 Scherer, 2001 Scott, 2007, Individual differences in reward responding explain placebo-induced expectations and effects, Neuron, 55, 325, 10.1016/j.neuron.2007.06.028 Slevin, 2005, Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor, J Neurosurg, 102, 216, 10.3171/jns.2005.102.2.0216 Stover, 2005, Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease, Arch Neurol, 62, 1833, 10.1001/archneur.62.12.1833 Vase, 2005, Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms, Pain, 115, 338, 10.1016/j.pain.2005.03.014